Association of sarcopenia with osteoporosis in patients with chronic obstructive pulmonary disease

Chua, Jamie; Tee, Michael L.

doi:10.1016/j.afos.2020.07.004

Cited by 12 publications

(9 citation statements)

References 21 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, data about ICS are not conclusive despite strong evidence currently supporting the higher risk of fragility fractures in patients receiving systemic corticosteroids [ 32 ]. Moreover, to date, no studies have assessed the association between ICS and sarcopenia [ 46 ]. In light of these considerations, the comprehensive management of COPD patients should address other critical issues related to long term corticosteroid therapies, including diabetes or sarcopenia, that might have crucial effects on the risk of falls and fractures [ 5 , 47 ].…”

Section: Long-term Corticosteroids Therapy In Copd Patientsmentioning

confidence: 99%

Osteosarcopenia in Patients with Chronic Obstructive Pulmonary Diseases: Which Pathophysiologic Implications for Rehabilitation?

Lippi

Folli

Curci

et al. 2022

IJERPH

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a burdensome condition affecting a growing number of people worldwide, frequently related to major comorbidities and functional impairment. In these patients, several factors might have a role in promoting both bone and muscle loss, including systemic inflammation, corticosteroid therapies, sedentary behaviours, deconditioning, malnutrition, smoking habits, and alcohol consumption. On the other hand, bone and muscle tissues share several linkages from functional, embryological, and biochemical points of view. Osteosarcopenia has been recently defined by the coexistence of osteoporosis and sarcopenia, but the precise mechanisms underpinning osteosarcopenia in patients with COPD are still unknown. In this scenario, a deeper understanding of the molecular basis of osteosarcopenia might guide clinicians in a personalized approach integrating skeletal muscle health with the pulmonary rehabilitation framework in COPD. Taken together, our results summarized the currently available evidence about the multilevel interactions between osteosarcopenia and COPD to pave the way for a comprehensive approach targeting the most common risk factors of these pathological conditions. Further studies are needed to clarify the role of modern clinical strategies and telemedicine solutions to optimize healthcare delivery in patients with COPD, including osteopenia, osteoporosis, and sarcopenia screening in these subjects.

show abstract

Section: Long-term Corticosteroids Therapy In Copd Patientsmentioning

confidence: 99%

Osteosarcopenia in Patients with Chronic Obstructive Pulmonary Diseases: Which Pathophysiologic Implications for Rehabilitation?

Lippi

Folli

Curci

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Sarcopenia, a geriatric disease characterized by a progressive loss of skeletal muscle mass and loss of muscle function, constitutes a rising, often undiagnosed health problem. The relationship between the sarcopenia and osteoporosis in chronic obstructive pulmonary disease [ 5 ], chronic kidney disease [ 6 ], primary biliary cholangitis [ 7 ] has been well developed. It is also confirmed that skeletal muscle mass is independently associated with osteoporosis in patients with T2DM [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Creatinine-to-cystatin C ratio as a marker of sarcopenia for identifying osteoporosis in male patients with type 2 diabetes mellitus

Dai

2022

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background Type 2 diabetes mellitus (T2DM) is associated with the increased incidence rate of sarcopenia and osteoporosis. Serum creatinine-to-cystatin C ratio (CCR) is a novel and simple tool which can be used as an index of sarcopenia. This study aims to investigate the association between CCR and osteoporosis as well as bone mineral density (BMD) in T2DM patients. Methods Four hundred eighteen T2DM patients were recruited, including 166 females and 252 males. General information, BMD data and laboratory data were collected. The correlation between CCR, BMD, bone metabolism markers and osteoporosis was explored by spearman correlation, receiver-operating characteristic (ROC) curve analysis and multiple regression analysis. Results Spearman correlation analysis showed that there was a positive correlation between CCR and BMD as well as serum calcium in male patients (r = 0.181–0.381, P < 0.01), but such correlation was not found in the female group. In multivariate regression analysis, it was found that there was a significant correlation between CCR and BMD of total lumbar spine, hip as well as femoral neck in male patients. ROC curve showed that the optimal cut-off value of CCR for predicting osteoporosis in male patients was 6.73 with the sensitivity of 88% and specificity of 63%. Conclusion In male T2DM patients, CCR was negatively correlated with osteoporosis and positively correlated with BMD.

show abstract

“…There are many common risk factors between sarcopenia and osteoporosis in COPD, including systemic inflammation (such as enhanced tumor necrosis factor (TNF)-α and IL-6), cigarette smoking, hypoxemia and/or hypercapnia, malnutrition, oxidative stress and reduced level of physical activity ( 8 , 23 ). Up to 70% of COPD patients with osteoporosis also show signs of muscle wasting ( 24 ), and sarcopenia is also an independent risk factor for osteoporosis in patients with COPD ( 13 ). Therefore, we hypothesize that there are interactions between muscle and bone comorbidities in COPD.…”

Section: Muscle-bone Crosstalkmentioning

confidence: 99%

Muscle-Bone Crosstalk in Chronic Obstructive Pulmonary Disease

Zhang

Sun

2021

Front. Endocrinol.

View full text Add to dashboard Cite

Sarcopenia and osteoporosis are common musculoskeletal comorbidities of chronic obstructive pulmonary disease (COPD) that seriously affect the quality of life and prognosis of the patient. In addition to spatially mechanical interactions, muscle and bone can also serve as endocrine organs by producing myokines and osteokines to regulate muscle and bone functions, respectively. As positive and negative regulators of skeletal muscles, the myokines irisin and myostatin not only promote/inhibit the differentiation and growth of skeletal muscles, but also regulate bone metabolism. Both irisin and myostatin have been shown to be dysregulated and associated with exercise and skeletal muscle dysfunction in COPD. During exercise, skeletal muscles produce a large amount of IL-6 which acts as a myokine, exerting at least two different conflicting functions depending on physiological or pathological conditions. Remarkably, IL-6 is highly expressed in COPD, and considered to be a biomarker of systemic inflammation, which is associated with both sarcopenia and bone loss. For osteokines, receptor activator of nuclear factor kappa-B ligand (RANKL), a classical regulator of bone metabolism, was recently found to play a critical role in skeletal muscle atrophy induced by chronic cigarette smoke (CS) exposure. In this focused review, we described evidence for myokines and osteokines in the pathogenesis of skeletal muscle dysfunction/sarcopenia and osteoporosis in COPD, and proposed muscle-bone crosstalk as an important mechanism underlying the coexistence of muscle and bone diseases in COPD.

show abstract

Association of sarcopenia with osteoporosis in patients with chronic obstructive pulmonary disease

Cited by 12 publications

References 21 publications

Osteosarcopenia in Patients with Chronic Obstructive Pulmonary Diseases: Which Pathophysiologic Implications for Rehabilitation?

Osteosarcopenia in Patients with Chronic Obstructive Pulmonary Diseases: Which Pathophysiologic Implications for Rehabilitation?

Creatinine-to-cystatin C ratio as a marker of sarcopenia for identifying osteoporosis in male patients with type 2 diabetes mellitus

Muscle-Bone Crosstalk in Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About